In today’s COVID-19 environment, more than ever, the myMatrixx team understands how to innovate and adapt to the changing workforce conditions. Our mission, to provide you with the highest level of customized service, has never been more important. We care deeply about our partners and their injured workers, and we are committed to providing you with the comprehensive information and resources you need to make decisions to support and grow your business.
Please use this resource to stay informed on how myMatrixx is addressing COVID-19 and check in often, as this page is updated frequently.
Image
COVID-19 Helpful Resources
Learn what the Coronavirus is, how it started, symptoms, prevention, and more:
COVID-19 Position Paper
myMatrixx View on COVID-19 Vaccination and Workers' Compensation Coverage
Upcoming NWCDC Panel to Feature myMatrixx President Mike Cirillo
May 17, 2021
In an upcoming webcast for the National Workers' Compensation and Disability Conference (NWCDC,) myMatrixx President, Mike Cirillo, will be a featured speaker along with other leaders in the field.
Learn more
myMatrixx Experts Featured in Industry Publications After Release of 2020 Drug Trend Report
May 10, 2021
In articles for industry publications WCI Weekly and WorkersCompensation.com, myMatrixx experts highlighted some of the key takeaways from the newly released 2020 Drug Trend Report.
Learn more
Kloxxado Receives FDA Approval for Opioid Overdoses
April 30, 2021
The U.S. Food and Drug Administration (FDA) approved Kloxxado™ (naloxone) nasal spray, 8mg, on April 29, 2021.
Learn more
myMatrixx Keeps Pressure on Spending and Identifies Key COVID-Related Effects in 2020 Drug Trend Report
April 28, 2021
In the wake of an unprecedented year for workers’ compensation pharmacy, myMatrixx was able to achieve positive outcomes, according to the newly released 2020 Drug Trend Report.
Learn more
Three Drugs on the Horizon to Watch in Workers’ Comp Pharmacy
April 21, 2021
As we continue to move into 2021, two of the biggest concerns in workers’ compensation pharmaceuticals remain the ongoing COVID-19 pandemic and the opioid misuse crisis.
Learn more
myMatrixx Speaks to Risk & Insurance on Pain Management and Psychotropic Drugs Ahead of NWCDC Presentation
March 24, 2021
myMatrixx Chief Clinical Officer, Phil Walls, recently appeared in a piece for Risk & Insurance on the important lessons the COVID-19 pandemic has taught workers’ compensation about behavioral health and psychotropic drug use.
Learn more
Janssen (Johnson & Johnson) COVID-19 Vaccine Granted Emergency Use Authorization
March 02, 2021
On February 27, 2021, Emergency Use Authorization (EUA) was granted to Janssen’s (Johnson & Johnson) COVID-19 vaccine (Ad26.COV2.S), by the U.S. Food and Drug Administration (FDA).
Learn more
myMatrixx Position on COVID-19 Vaccination and Workers' Compensation Coverage
February 20, 2021
myMatrixx Releases Position Paper on COVID-19 Vaccination and Workers' Compensation Coverage
Learn more